Based on the overall assessment, nusinersen was granted the status of “therapeutic innovation” and received reimbursement for patients with EO type I and LO type II and III SMA patients, hereby excluding patients with more than four copies of the SMN2 gene (AIFA, 2017a; AIFA, 2017b). The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.